← All trials
NCT07024888
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 16, 2025
- Primary completion
- May 28, 2025
- Completion date
- May 28, 2025
- First posted
- Jun 17, 2025
- Last posted
- Jun 18, 2025
- Enrollment
- 36
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sunshine Lake Pharma Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.